CD3 limits the efficacy of TCR gene therapy in vivo

Blood

Volumn 118, Issue 13, 2011, Pages 3528-3537

  Ahmadi, Maryam ^a   King, Judith W ^a   Xue, Shao An ^a   Voisine, Cécile ^a   Holler, Angelika ^a   Wright, Graham P ^a   Waxman, Jonathan ^b   Morris, Emma ^a,c   Stauss, Hans J ^a,c  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR GROWTH; TUMOR VOLUME;

EID: 80053377123     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-346338     Document Type: Article

References (37)

1. Clay TM, Custer MC, Sachs J, et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers antitumor reactivity. J Immunol. 1999;163(1):507- 513.
2. Cooper LJ, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol. 2000;74(17):8207-8212. (Pubitemid 30641669)
3. Kessels HW, Wolkers MC, van den Boom MD, van der Valk MA, Schumacher TN. Immunotherapy through TCR gene transfer. Nat Immunol. 2001;2(10):957-961. (Pubitemid 32976169)
4. Heemskerk MH, Hoogeboom M, Hagedoorn R, et al. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med. 2004;199(7):885-894. (Pubitemid 38481080)
5. Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol. 2001;2(10):962-970. (Pubitemid 32976170)
6. Xue SA, Gao L, Hart D, et al. Elimination of human leukemia cells in NOD/SCID mice by WT1- TCR gene-transduced human T cells. Blood. 2005;106(9):3062-3067. (Pubitemid 41565901)
7. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314(5796):126-129. (Pubitemid 44547756)
8. Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011; 19(3):620-626.
9. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917-924.
10. Goff SL, Johnson LA, Black MA, et al. Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion. Cancer Immunol Immunother. 2010;59(10):1551-1560.
11. Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol. 2001;1(3):209-219. (Pubitemid 33741959)
12. Margulies DH. TCR avidity: it's not how strong you make it, it's how you make it strong. Nat Immunol. 2001;2(8):669-670. (Pubitemid 32747153)
13. Hofmann M, Radsak M, Rechtsteiner G, et al. T cell avidity determines the level of CTL activation. Eur. J. Immunol. 2004;34(7):1798-1806. (Pubitemid 39256062)
14. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science. 1996;273(5271):104-106. (Pubitemid 26255435)
15. Cohen CJ, Li YF, El-Gamil M, et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 2007;67(8):3898-3903. (Pubitemid 46762178)
16. Kuball J, Dossett ML, Wolfl M, et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood. 2007; 109(6):2331-2338. (Pubitemid 46425872)
17. Thomas S, Xue SA, Cesco-Gaspere M, et al. Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J Immunol. 2007;179(9):5803-5810.
18. Sebestyen Z, Schooten E, Sals T, et al. Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer. J Immunol. 2008; 180(11):7736-7746.
19. Reichardt W, Durr C, Von Elverfedt D, et al. Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J Immunol. 2008;181(7):4770-4779.
20. Letourneur F, Malissen B. Derivation of a T cell hybridoma variant deprived of functional T cell receptor alpha and beta chain transcripts reveals a nonfunctional alpha-mRNA of BW5147 origin. Eur J Immunol. 1989;19(12):2269- 2274. (Pubitemid 20024752)
21. DeMars R, Chang CC, Shaw S, Reitnauer PJ, Sondel PM. Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens. Hum Immunol. 1984;11(2):77-97. (Pubitemid 14046614)
22. Ljunggren HG, Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med. 1985;162(6):1745-1759. (Pubitemid 16149673)
23. Dahl AM, Beverley PC, Stauss HJ. A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J Immunol. 1996;157(1): 239-246. (Pubitemid 26190553)
24. Morris EC, Tsallios A, Bendle GM, Xue SA, Stauss HJ. A critical role of T cell antigen receptor- transduced MHC class I-restricted helper T cells in tumor protection. Proc Natl Acad Sci U S A 2005;102(22):7934-7939. (Pubitemid 40781041)
25. Szymczak AL, Workman CJ, Wang Y, et al. Correction of multi-gene deficiency in vivo using a single "self-cleaving" 2A peptide-based retroviral vector. Nat Biotechnol. 2004;22(5):589-594. (Pubitemid 38585911)
26. Scholten KB, Kramer D, Kueter EW, et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol. 2006;119(2):135-145.
27. Rechtsteiner G, Warger T, Hofmann M, et al. Precursor frequency can compensate for lower TCR expression in T cell competition during priming in vivo. Eur J Immunol. 2006;36(10):2613-2623. (Pubitemid 44608445)
28. Slifka MK, Whitton JL. Functional avidity maturation of CD8(+) T cells without selection of higher affinity TCR. Nat Immunol. 2001;2(8):711-717. (Pubitemid 32747160)
29. Bendle GM, Linnemann C, Hooijkaas AI, et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med. 2010;16(5):565-70.
30. Rosenberg SA. Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol Ther. 2010;18(10):1744-1745.
31. Sommermeyer D, Neudorfer J, Weinhold M, et al. Designer T cells by T cell receptor replacement. Eur J Immunol. 2006;36(11):3052-3059. (Pubitemid 44782577)
32. Heemskerk MH, Hagedoorn RS, van der Hoorn MA, et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood. 2007;109(1):235-243. (Pubitemid 46053064)
33. Hart DP, Xue SA, Thomas S, et al. Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells. Gene Ther. 2008;15(8):625-631.
34. Holler PD, Holman PO, Shusta EV, et al. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc Natl Acad Sci U S A. 2000; 97(10):5387-5392. (Pubitemid 30313728)
35. Li Y, Moysey R, Molloy PE, et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol. 2005; 23:349-354. (Pubitemid 41094424)
36. Robbins PF, Li YF, El-Gamil M, et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol. 2008;180(9):6116-6131.
37. Zhao Y, Bennett AD, Zheng Z, et al. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol. 2007;179(9):5845-5854.